EnVVeno Medical Reports Q1 2025 Financials and FDA Progress

enVVeno Medical Corporation has announced its financial results for the first quarter of 2025, maintaining a steady cash burn of $4 million. The company holds $38.9 million in cash, securing operations beyond the anticipated FDA decision on the VenoValve. The FDA's decision on the VenoValve is expected in the second half of 2025.

CEO Robert Berman highlighted the company's efforts in sharing trial data and engaging with vascular surgeons. enVVeno remains financially robust, gearing up for commercialization post-FDA approval.

Clinical updates reveal the completion of a six-month pre-clinical study for the enVVe valve, necessary before filing an Investigational Device Exemption expected mid-2025. The VenoValve targets a potential market of 2.5 million patients annually in the U.S.